Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03775850
Title A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Evelo Biosciences, Inc.
Indications

Advanced Solid Tumor

urinary bladder cancer

colorectal cancer

lung non-small cell carcinoma

gastroesophageal cancer

triple-receptor negative breast cancer

renal cell carcinoma

Therapies

EDP1503

EDP1503 + Pembrolizumab

Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
Highlands Oncology Group Rogers Arkansas 72758 United States Details
Florida Cancer Specialists Sarasota Florida 34232 United States Details
Stephenson Cancer Center Oklahoma City Oklahoma 73104 United States Details
Tennessee Oncology, PLLC Chattanooga Tennessee 37404 United States Details
Tennessee Oncology Nashville Tennessee 37203 United States Details
Centre de Recherche du CHUM Montréal Quebec H2X 0A9 Canada Details
Jewish General Hospital Montréal Quebec H3T1E2 Canada Details
CHU de Québec - Université Laval Québec G1R 2J6 Canada Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field